Injectable Rifampin Recalled Due to Failed Quality Specifications
Mylan Pharmaceuticals is recalling injectable Rifampin vials nationwide due to failed impurities and degradation specifications discovered during stability testing.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This FDA Class II recall involves an injectable pharmaceutical with failed quality specifications—impurity and degradation product levels exceeding established standards. No illnesses or hospitalizations have been reported, making this a risk-of-harm product where injury has not yet been documented.
Plain-English summary
Mylan Pharmaceuticals Inc is recalling Rifampin for Injection, USP (600 mg/vial) nationwide. The recall affects 33,893 vials due to failed impurities and degradation specifications.
During stability testing, Mylan found that related compounds in the affected lots were present at levels exceeding the established specifications. This failure means the product may not meet required quality standards.
The recall includes four specific lot numbers with varying expiration dates between December 2022 and April 2023. Patients receiving Rifampin from these lots may be affected.
Healthcare providers and patients should verify the lot number on their medication. If you have received Rifampin from one of the affected lots, contact your healthcare provider or pharmacist for guidance. Do not use recalled product and return it to the pharmacy for proper disposal.
The recalled product
- Product
- RIFAMPIN (RIFAMPIN)
- Brand
- RIFAMPIN
- Manufacturer
- Mylan Pharmaceuticals Inc
- Category
- Drug — Injectable Antibiotic
- Hazard
- impurity
- degradation-product
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (7)
- Lot #: 7008990
- exp. date Dec-2022
- 7009025
- exp. date Feb-2023
- 7009085
- 7009086
- exp. date Apr-2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · RIFAMPIN
- HighAntibiotic Rifampin Capsules Recalled for Subpotency and Quality Failures
FDA (Drugs) · 2024-02-07
- HighRifampin Capsules Recalled Due to Failed Impurity and Degradation Specification
FDA (Drugs) · 2024-02-07
- HighRifampin Antibiotic Capsules Recalled for Subpotency and Failed Specifications
FDA (Drugs) · 2024-02-07
- HighPrescription Rifampin Capsules Recalled Due to Failed Quality Specifications
FDA (Drugs) · 2023-01-25
- HighPrescription Rifampin Capsules Recalled for Failed Impurity Specifications
FDA (Drugs) · 2023-01-18
Same category
- SevereChloraPrep One-Step Applicators Recalled for Potential Packaging Seal Defects
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateQuality Choice Earwax Removal Kit Carbamide Peroxide Subpotent Drug Recall
FDA (Drugs) · 2026-07-22
- ModerateFamily Wellness Carbamide Peroxide Earwax Removal Kit Subpotent Drug
FDA (Drugs) · 2026-07-22
- ModerateTopCare Earwax Removal Kit Recalled for Subpotent Drug Content
FDA (Drugs) · 2026-07-22